Alecensa (alectinib)

Alecensa is a highly selective, central nervous system-active, oral medicine used for the treatment of people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is a tyrosine kinase inhibitor that targets ALK fusion proteins, preventing signalling within cancer cells to inhibit their growth and survival.

Alecensa is currently approved in over 80 countries as a first-line treatment for advanced (metastatic) ALK-positive NSCLC. It is also approved in over 90 countries for the treatment of ALK-positive advanced NSCLC patients whose disease has worsened after, or who could not tolerate treatment with, crizotinib.


Pharma Products
See all Pharma Products

This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.

please be aware that you are leaving this website.